Gut Microbiota Modulation for Early Dementia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating dementia are limited, with existing diagnostic techniques unable to detect the disease at early stages and available treatments showing limited effectiveness, particularly for mild Alzheimer's dementia.
Innovation Solution
The development of methods involving the measurement of NNN-trimethyl-5-aminovalerate and its precursors or metabolites in various samples to diagnose dementia, along with the use of specific agents to reduce these compounds or alter gut microbiota to treat the condition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cognitive testing is used for diagnosis, then diagnosis can be made once symptoms have developed, but early diagnosis before symptom development is not possible
Solution Approach 1:
The patent applies preliminary action by measuring NNN-trimethyl-5-aminovalerate levels before dementia symptoms manifest. The method detects elevated metabolite concentrations in blood or urine during the pre-symptomatic phase, enabling early intervention before cognitive decline becomes apparent through traditional testing.
Solution Approach 2:
The patent uses NNN-trimethyl-5-aminovalerate as an intermediary biomarker that connects gut microbiota dysbiosis to early dementia pathology. This metabolite serves as a measurable indicator that precedes clinical symptoms, allowing diagnosis through blood or urine analysis before cognitive testing would detect any impairment.
2Reliability
If conventional treatments are used for dementia, then limited therapeutic options are available, but treatment effectiveness is insufficient particularly for mild Alzheimer's dementia
Solution Approach 1:
The patent extracts and targets the specific metabolic pathway producing NNN-trimethyl-5-aminovalerate in the gut. By identifying and eliminating the causative metabolite through dietary intervention, probiotics, or enzymatic inhibitors, the treatment addresses the root cause rather than managing symptoms, providing a targeted therapy for mild Alzheimer's dementia.
Solution Approach 2:
The patent changes the metabolic parameter by reducing NNN-trimethyl-5-aminovalerate concentrations through intervention strategies. This involves modifying gut microbiota composition or activity to decrease production of the harmful metabolite, thereby reversing or preventing dementia progression through biochemical parameter adjustment.
3Reliability
If the concentration of NNN-trimethyl-5-aminovalerate is reduced, then cognitive function may be improved, but the mechanism by which gut microbiota affects cognition is not fully understood
Solution Approach 1:
The patent establishes a feedback mechanism by measuring NNN-trimethyl-5-aminovalerate levels before and after intervention. This quantitative approach provides evidence that reducing the metabolite concentration correlates with cognitive improvement, building empirical understanding of the gut-brain axis mechanism while maintaining treatment efficacy.
Data Source
AI summary
The present invention concerns new approaches for the diagnosis and treatment of dementia diseases. In particular, the present invention pertains to new markers for diagnosing dementia diseases as well as to new targets for the treatment of dementia diseases.